Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO)

Version 1 : Received: 20 February 2024 / Approved: 20 February 2024 / Online: 20 February 2024 (16:43:17 CET)

A peer-reviewed article of this Preprint also exists.

Zwimpfer, T.A.; Bilir, E.; Gasimli, K.; Cokan, A.; Bizzarri, N.; Razumova, Z.; Kacperczyk-Bartnik, J.; Nikolova, T.; Pletnev, A.; Kahramanoglu, I.; Shushkevich, A.; Strojna, A.; Theofanakis, C.; Cicakova, T.; Vetter, M.; Montavon, C.; Morgan, G.; Heinzelmann-Schwarz, V. Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO). Cancers 2024, 16, 1155. Zwimpfer, T.A.; Bilir, E.; Gasimli, K.; Cokan, A.; Bizzarri, N.; Razumova, Z.; Kacperczyk-Bartnik, J.; Nikolova, T.; Pletnev, A.; Kahramanoglu, I.; Shushkevich, A.; Strojna, A.; Theofanakis, C.; Cicakova, T.; Vetter, M.; Montavon, C.; Morgan, G.; Heinzelmann-Schwarz, V. Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO). Cancers 2024, 16, 1155.

Abstract

Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions. A total of 144 respondents completed the survey and 133 respondents were included in the final analysis. Most participants were gynecologic oncologists (43.6%) and medical oncologists (33.8%), and 77.4% (n=103) were involved in chemotherapy treatment. More than 73% of participants experienced >5 HSRs to platinum and taxane per year. Pre-medication and a new attempt with platinum or taxane chemotherapy were used in 84.8% and 92.5% of Grade 1-2 HSR to platinum and taxane, respectively. In contrast, desensitization was used in 49.4% and 41.8% of Grade 3-4 HSR to platinum and taxane, respectively. Most participants strongly emphasized the need to standardize the management of platinum and taxane HSR in gynecologic cancer. Our study showed that HSR in gynecologic cancer is common, but management is variable and the use of desensitization is low. In addition, the need for guidance on the management of platinum- and taxane-induced HSR in gynecologic cancer was highlighted.

Keywords

Desensitization; Platinum; Taxane; Hypersensitivity reaction; Gynecologic cancer; Chemotherapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.